Los inhibidores SGLT2: una mirada al futuro del tratamiento de la insuficiencia cardiaca / Sodium-glucose cotransporter 2 inhibitors for the management of heart failure
Rev. méd. Chile
; 150(12): 1647-1654, dic. 2022. ilus, tab
Article
in Es
| LILACS
| ID: biblio-1515395
Responsible library:
CL1.1
ABSTRACT
Heart failure (HF) is a global health problem. There is a strong association h between HF and type 2 diabetes mellitus (DM2), with an increasing prevalence of patients having both conditions concomitantly. Sodium-glucose cotransporter 2 inhibitors (ISGLT2) significantly reduce cardiovascular events, including cardiovascular death. In this article we will focus on the current evidence about the effectiveness of these medications in adults with heart failure with reduced or preserved ejection fraction.
Key words
Full text:
1
Index:
LILACS
Main subject:
Diabetes Mellitus, Type 2
/
Sodium-Glucose Transporter 2 Inhibitors
/
Heart Failure
Limits:
Humans
Language:
Es
Journal:
Rev. méd. Chile
Journal subject:
MEDICINA
Year:
2022
Type:
Article